A novel polymorphic allele of human arylacetamide deacetylase leads to decreased enzyme activity

Drug Metabolism and Disposition

Volumn 40, Issue 6, 2012, Pages 1183-1190

  Shimizu, Mai ^a   Fukami, Tatsuki ^a   Kobayashi, Yuki ^a   Takamiya, Masataka ^b   Aoki, Yasuhiro ^b   Nakajima, Miki ^a   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLACETAMIDE DEACETYLASE; FLUTAMIDE; GENOMIC DNA; GLUTAMINE; HYDROLASE; MESSENGER RNA; PHENACETIN; RIFAMPICIN; SERINE PROTEINASE; UNCLASSIFIED DRUG;

AFRICAN AMERICAN; ALLELE; ANIMAL CELL; ARTICLE; ARYLACETAMIDE DEACETYLASE GENE; CARBOXY TERMINAL SEQUENCE; CELL STRAIN COS7; CONTROLLED STUDY; DOWN REGULATION; DRUG CLEARANCE; ENZYME ACTIVITY; ENZYME POLYMORPHISM; ETHNIC GROUP; EUROPEAN AMERICAN; GENE; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; JAPANESE; KOREAN; LIVER MICROSOME; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

ALLELES; ANIMALS; CARBOXYLIC ESTER HYDROLASES; CERCOPITHECUS AETHIOPS; COS CELLS; ENZYME ACTIVATION; HUMANS; MICROSOMES, LIVER; POLYMORPHISM, GENETIC;

EID: 84862095906     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.044883     Document Type: Article

References (29)

1. Benson MD, Liepnieks JJ, Yazaki M, Yamashita T, Hamidi Asl K, Guenther B, and Kluve-Beckerman B (2001) A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene. Genomics 72:272-277. (Pubitemid 32281528)
2. Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, and La Du BN (2000) Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 28:1335-1342.
3. Cook LJ, Ho LW, Wang L, Terrenoire E, Brayne C, Evans JG, Xuereb J, Cairns NJ, Turic D, Hollingworth P, et al. (2005) Candidate gene association studies of genes involved in neuronal cholinergic transmission in Alzheimer's disease suggests choline acetyltransferase as a candidate deserving further study. Am J Med Genet B Neuropsychiatr Genet 132B:5-8. (Pubitemid 40066186)
4. Darvesh S, Hopkins DA, and Geula C (2003) Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 4:131-138. (Pubitemid 37271383)
5. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, and Furlong CE (1996) The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 14:334-336.
6. Evans WE and McLeod HL (2003) Pharmacogenomics: drug disposition, drug targets and side effects. N Engl J Med 348:538-549. (Pubitemid 36159890)
7. Evans WE and Relling MV (2004) Moving towards individualized medicine with pharmacogenomics. Nature 429:464-468. (Pubitemid 38715141)
8. Frick C, Atanasov AG, Arnold P, Ozols J, and Odermatt A (2004) Appropriate function of 11β-hydroxysteroid dehydrogenase type 1 in the endoplasmic reticulum lumen is dependent on its N-terminal region sharing similar topological determinants with 50-kDa esterase. J Biol Chem 279:31131-31138. (Pubitemid 39037775)
9. Gago-Dominguez M, Yuan JM, Castelao JE, Ross RK, and Yu MC (1999) Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer 81:542-548. (Pubitemid 29458812)
10. Goda R, Nagai D, Akiyama Y, Nishikawa K, Ikemoto I, Aizawa Y, Nagata K, and Yamazoe Y (2006) Detection of new N-oxidized metabolite of flutamide, N-[4-nitro-3-(trifluoromethyl) phenyl]hydroxylamide, in human liver microsomes and urine of prostate cancer patients. Drug Metab Dispos 34:828-835.
11. Hioki T, Fukami T, Nakajima M, and Yokoi T (2011) Human paraoxonase 1 is the enzyme responsible for pilocarpine hydrolysis. Drug Metab Dispos 39:1345-1352.
12. Jamis-Dow CA, Katki AG, Collins JM, and Klecker RW (1997) Rifampin and rifabutin and their metabolism by human liver esterases. Xenobiotica 27:1015-1024. (Pubitemid 27450594)
13. Jensen CB and Jollow DJ (1991) The role of N-hydroxyphenetidine in phenacetin-induced hemolytic anemia. Toxicol Appl Pharmacol 111:1-12.
14. Kobayashi Y, Fukami T, Shimizu M, Nakajima M, and Yokoi T (2012) Contributions of arylacetamide deacetylase and carboxylesterase 2 to flutamide hydrolysis in human liver. Drug Metab Dispos doi:10.1124/dmd.112.044537.
15. Lo V, Erickson B, Thomason-Hughes M, Ko KW, Dolinsky VW, Nelson R, and Lehner R (2010) Arylacetamide deacetylase attenuates fatty-acid-induced triacylglycerol accumulation in rat hepatoma cells. J Lipid Res 51:368-377.
16. Nakajima A, Fukami T, Kobayashi Y, Watanabe A, Nakajima M, and Yokoi T (2011) Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. Biochem Pharmacol 82:1747-1756.
17. Probst MR, Beer M, Beer D, Jenö P, Meyer UA, and Gasser R (1994) Human liver arylacetamide deacetylase: molecular cloning of a novel esterase involved in the metabolic activation of arylamine carcinogens with high sequence similarity to hormone-sensitive lipase. J Biol Chem 269:21650-21656.
18. Probst MR, Jenö P, and Meyer UA (1991) Purification and characterization of a human liver arylacetamide deacetylase. Biochem Biophys Res Commun 177:453-459.
19. Scacchi R, Gambina G, Moretto G, and Corbo RM (2009) Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with donepezil and rivastigmine. Am J Med Genet B Neuropsychiatr Genet 150B: 502-507.
20. Shudo K, Ohta T, Orihara Y, Okamoto T, Nagao M, Takahashi Y, and Sugimura T (1978) Mutagenicities of phenacetin and its metabolites. Mutat Res 58:367-370. (Pubitemid 9054954)
21. Sicardi SM, Martiarena JL, and Iglesias MT (1991) Mutagenic and analgesic activities of aniline derivatives. J Pharm Sci 80:761-764.
22. Tiwari R, Köffel R, and Schneiter R (2007) An acetylation/ deacetylation cycle controls the export of sterols and steroids from S. cerevisiae. EMBO J 26:5109-5119. (Pubitemid 350261287)
23. Trickett JI, Patel DD, Knight BL, Saggerson ED, Gibbons GF, and Pease RJ (2001) Characterization of the rodent genes for arylacetamide deacetylase, a putative microsomal lipase, and evidence for transcriptional regulation. J Biol Chem 276:39522-39532.
24. Tsuchiya Y, Nakajima M, Kyo S, Kanaya T, Inoue M, and Yokoi T (2004) Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Res 64:3119-3125. (Pubitemid 38581412)
25. Wain HM, Bruford EA, Lovering RC, Lush MJ, Wright MW, and Povey S (2002) Guidelines for human gene nomenclature. Genomics 79:464-470. (Pubitemid 34274283)
26. Watanabe A, Fukami T, Nakajima M, Takamiya M, Aoki Y, and Yokoi T (2009) Human arylacetamide deacetylase is a principal enzyme in flutamide hydrolysis. Drug Metab Dispos 37:1513-1520.
27. Watanabe A, Fukami T, Takahashi S, Kobayashi Y, Nakagawa N, Nakajima M, and Yokoi T (2010) Arylacetamide deacetylase is a determinant enzyme for the difference in hydrolase activities of phenacetin and acetaminophen. Drug Metab Dispos 38:1532-1537.
28. Wirth PJ, Alewood P, Calder I, and Thorgeirsson SS (1982) Mutagenicity of N-hydroxy-2-acetylaminofluorene and N-hydroxy-phenacetin and their respective deacetylated metabolites in nitroreductase deficient Salmonella TA98FR and TA100FR. Carcinogenesis 3:167-170. (Pubitemid 12120577)
29. Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, Malcolm R, Johnson JA, Youngblood GL, Sweet DH, et al. (2008) Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet 82:1241-1248.